Increased  ||| S:0 E:10 ||| VBN
hip  ||| S:10 E:14 ||| JJ
fracture  ||| S:14 E:23 ||| NN
and  ||| S:23 E:27 ||| CC
mortality  ||| S:27 E:37 ||| NN
in  ||| S:37 E:40 ||| IN
chronic  ||| S:40 E:48 ||| JJ
kidney  ||| S:48 E:55 ||| NN
disease  ||| S:55 E:63 ||| NN
individuals ||| S:63 E:74 ||| NNS
:  ||| S:74 E:76 ||| :
the  ||| S:76 E:80 ||| DT
importance  ||| S:80 E:91 ||| NN
of  ||| S:91 E:94 ||| IN
competing  ||| S:94 E:104 ||| VBG
risks  ||| S:104 E:110 ||| NNS
Many  ||| S:110 E:115 ||| JJ
studies  ||| S:115 E:123 ||| NNS
have  ||| S:123 E:128 ||| VBP
shown  ||| S:128 E:134 ||| VBN
a  ||| S:134 E:136 ||| DT
correlation  ||| S:136 E:148 ||| NN
between  ||| S:148 E:156 ||| IN
chronic  ||| S:156 E:164 ||| JJ
kidney  ||| S:164 E:171 ||| NN
disease  ||| S:171 E:179 ||| NN
( ||| S:179 E:180 ||| -LRB-
CKD ||| S:180 E:183 ||| NNP
)  ||| S:183 E:185 ||| -RRB-
and  ||| S:185 E:189 ||| CC
fracture ||| S:189 E:197 ||| NN
.  ||| S:197 E:199 ||| .
However ||| S:199 E:206 ||| RB
,  ||| S:206 E:208 ||| ,
increased  ||| S:208 E:218 ||| VBN
mortality  ||| S:218 E:228 ||| NN
in  ||| S:228 E:231 ||| IN
CKD  ||| S:231 E:235 ||| NNP
patients  ||| S:235 E:244 ||| NNS
is  ||| S:244 E:247 ||| VBZ
a  ||| S:247 E:249 ||| DT
competing  ||| S:249 E:259 ||| JJ
risk  ||| S:259 E:264 ||| NN
scenario  ||| S:264 E:273 ||| NN
not  ||| S:273 E:277 ||| RB
accounted  ||| S:277 E:287 ||| VBN
for  ||| S:287 E:291 ||| IN
in  ||| S:291 E:294 ||| IN
previous  ||| S:294 E:303 ||| JJ
studies ||| S:303 E:310 ||| NNS
.  ||| S:310 E:312 ||| .
Our  ||| S:312 E:316 ||| PRP$
aim  ||| S:316 E:320 ||| NN
was  ||| S:320 E:324 ||| VBD
to  ||| S:324 E:327 ||| TO
investigate  ||| S:327 E:339 ||| VB
the  ||| S:339 E:343 ||| DT
true  ||| S:343 E:348 ||| JJ
impact  ||| S:348 E:355 ||| NN
of  ||| S:355 E:358 ||| IN
CKD  ||| S:358 E:362 ||| NNP
on  ||| S:362 E:365 ||| IN
hip  ||| S:365 E:369 ||| JJ
fracture  ||| S:369 E:378 ||| NN
after  ||| S:378 E:384 ||| IN
accounting  ||| S:384 E:395 ||| NN
for  ||| S:395 E:399 ||| IN
a  ||| S:399 E:401 ||| DT
competing  ||| S:401 E:411 ||| JJ
risk  ||| S:411 E:416 ||| NN
with  ||| S:416 E:421 ||| IN
death ||| S:421 E:426 ||| NN
.  ||| S:426 E:428 ||| .
We  ||| S:428 E:431 ||| PRP
conducted  ||| S:431 E:441 ||| VBD
a  ||| S:441 E:443 ||| DT
population-based  ||| S:443 E:460 ||| JJ
cohort  ||| S:460 E:467 ||| JJ
study  ||| S:467 E:473 ||| NN
to  ||| S:473 E:476 ||| TO
determine  ||| S:476 E:486 ||| VB
the  ||| S:486 E:490 ||| DT
impact  ||| S:490 E:497 ||| NN
of  ||| S:497 E:500 ||| IN
CKD  ||| S:500 E:504 ||| NNP
on  ||| S:504 E:507 ||| IN
hip  ||| S:507 E:511 ||| JJ
fractures  ||| S:511 E:521 ||| NN
in  ||| S:521 E:524 ||| IN
individuals  ||| S:524 E:536 ||| NNS
aged  ||| S:536 E:541 ||| VBN
â‰¥50years  ||| S:541 E:550 ||| CD
old  ||| S:550 E:554 ||| JJ
registered  ||| S:554 E:565 ||| NN
in  ||| S:565 E:568 ||| IN
the  ||| S:568 E:572 ||| DT
SIDIAP ||| S:572 E:578 ||| NNP
( ||| S:578 E:579 ||| -LRB-
Q ||| S:579 E:580 ||| NNP
)  ||| S:580 E:582 ||| -RRB-
database  ||| S:582 E:591 ||| NN
( ||| S:591 E:592 ||| -LRB-
representative  ||| S:592 E:607 ||| NN
of  ||| S:607 E:610 ||| IN
1.9  ||| S:610 E:614 ||| CD
million  ||| S:614 E:622 ||| CD
people  ||| S:622 E:629 ||| NNS
in  ||| S:629 E:632 ||| IN
Catalonia ||| S:632 E:641 ||| NNP
,  ||| S:641 E:643 ||| ,
Spain ||| S:643 E:648 ||| NNP
) ||| S:648 E:649 ||| -RRB-
.  ||| S:649 E:651 ||| .
Cox  ||| S:651 E:655 ||| NNP
regression  ||| S:655 E:666 ||| NN
was  ||| S:666 E:670 ||| VBD
used  ||| S:670 E:675 ||| VBN
to  ||| S:675 E:678 ||| TO
estimate  ||| S:678 E:687 ||| VB
hazard  ||| S:687 E:694 ||| JJ
ratio  ||| S:694 E:700 ||| NN
( ||| S:700 E:701 ||| -LRB-
HR ||| S:701 E:703 ||| NNP
)  ||| S:703 E:705 ||| -RRB-
for  ||| S:705 E:709 ||| IN
death  ||| S:709 E:715 ||| NN
and  ||| S:715 E:719 ||| CC
hip  ||| S:719 E:723 ||| JJ
fracture  ||| S:723 E:732 ||| NN
according  ||| S:732 E:742 ||| VBG
to  ||| S:742 E:745 ||| TO
CKD  ||| S:745 E:749 ||| NNP
status ||| S:749 E:755 ||| NN
.  ||| S:755 E:757 ||| .
A  ||| S:757 E:759 ||| DT
competing  ||| S:759 E:769 ||| JJ
risk  ||| S:769 E:774 ||| NN
( ||| S:774 E:775 ||| -LRB-
Fine  ||| S:775 E:780 ||| NNP
and  ||| S:780 E:784 ||| CC
Gray ||| S:784 E:788 ||| NNP
)  ||| S:788 E:790 ||| -RRB-
model  ||| S:790 E:796 ||| NN
was  ||| S:796 E:800 ||| VBD
fitted  ||| S:800 E:807 ||| VBN
to  ||| S:807 E:810 ||| TO
estimate  ||| S:810 E:819 ||| VB
sub-HR  ||| S:819 E:826 ||| JJ
for  ||| S:826 E:830 ||| IN
hip  ||| S:830 E:834 ||| JJ
fracture  ||| S:834 E:843 ||| NN
in  ||| S:843 E:846 ||| IN
CKD  ||| S:846 E:850 ||| NNP
or  ||| S:850 E:853 ||| CC
CKD-free  ||| S:853 E:862 ||| JJ
patients  ||| S:862 E:871 ||| NNS
accounting  ||| S:871 E:882 ||| NN
for  ||| S:882 E:886 ||| IN
differential  ||| S:886 E:899 ||| JJ
mortality ||| S:899 E:908 ||| NN
.  ||| S:908 E:910 ||| .
A  ||| S:910 E:912 ||| DT
total  ||| S:912 E:918 ||| NN
of  ||| S:918 E:921 ||| IN
873,073  ||| S:921 E:929 ||| NNP
( ||| S:929 E:930 ||| -LRB-
32,934  ||| S:930 E:937 ||| NNP
( ||| S:937 E:938 ||| -LRB-
3.8 ||| S:938 E:941 ||| CD
% ||| S:941 E:942 ||| NN
)  ||| S:942 E:944 ||| -RRB-
CKD ||| S:944 E:947 ||| NNP
)  ||| S:947 E:949 ||| -RRB-
patients  ||| S:949 E:958 ||| NNS
were  ||| S:958 E:963 ||| VBD
observed  ||| S:963 E:972 ||| VBN
for  ||| S:972 E:976 ||| IN
3  ||| S:976 E:978 ||| CD
years ||| S:978 E:983 ||| NNS
.  ||| S:983 E:985 ||| .
During  ||| S:985 E:992 ||| IN
follow-up ||| S:992 E:1001 ||| NNP
,  ||| S:1001 E:1003 ||| ,
4,823  ||| S:1003 E:1009 ||| NNP
( ||| S:1009 E:1010 ||| -LRB-
14.6 ||| S:1010 E:1014 ||| CD
% ||| S:1014 E:1015 ||| NN
)  ||| S:1015 E:1017 ||| -RRB-
CKD  ||| S:1017 E:1021 ||| NNP
and  ||| S:1021 E:1025 ||| CC
36,328  ||| S:1025 E:1032 ||| NNP
( ||| S:1032 E:1033 ||| -LRB-
4.3 ||| S:1033 E:1036 ||| CD
% ||| S:1036 E:1037 ||| NN
)  ||| S:1037 E:1039 ||| -RRB-
CKD-free  ||| S:1039 E:1048 ||| JJ
participants  ||| S:1048 E:1061 ||| NNS
died  ||| S:1061 E:1066 ||| VBD
( ||| S:1066 E:1067 ||| -LRB-
HR ||| S:1067 E:1069 ||| NNP
,  ||| S:1069 E:1071 ||| ,
1.83  ||| S:1071 E:1076 ||| CD
[ ||| S:1076 E:1077 ||| -LRB-
95 ||| S:1077 E:1079 ||| CD
%  ||| S:1079 E:1081 ||| NN
CI ||| S:1081 E:1083 ||| NNP
,  ||| S:1083 E:1085 ||| ,
1.78-1.89 ||| S:1085 E:1094 ||| CD
] ||| S:1094 E:1095 ||| CD
) ||| S:1095 E:1096 ||| -RRB-
,  ||| S:1096 E:1098 ||| ,
whilst  ||| S:1098 E:1105 ||| CD
522  ||| S:1105 E:1109 ||| CD
( ||| S:1109 E:1110 ||| -LRB-
1.59 ||| S:1110 E:1114 ||| CD
% ||| S:1114 E:1115 ||| NN
)  ||| S:1115 E:1117 ||| -RRB-
and  ||| S:1117 E:1121 ||| CC
6,292  ||| S:1121 E:1127 ||| NNP
( ||| S:1127 E:1128 ||| -LRB-
0.75 ||| S:1128 E:1132 ||| CD
% ||| S:1132 E:1133 ||| NN
)  ||| S:1133 E:1135 ||| -RRB-
sustained  ||| S:1135 E:1145 ||| VBD
hip  ||| S:1145 E:1149 ||| JJ
fractures ||| S:1149 E:1158 ||| NN
,  ||| S:1158 E:1160 ||| ,
respectively ||| S:1160 E:1172 ||| RB
.  ||| S:1172 E:1174 ||| .
Adjusted  ||| S:1174 E:1183 ||| NNP
Cox  ||| S:1183 E:1187 ||| NNP
models  ||| S:1187 E:1194 ||| NNS
showed  ||| S:1194 E:1201 ||| VBD
a  ||| S:1201 E:1203 ||| DT
significantly  ||| S:1203 E:1217 ||| RB
increased  ||| S:1217 E:1227 ||| VBN
risk  ||| S:1227 E:1232 ||| NN
of  ||| S:1232 E:1235 ||| IN
hip  ||| S:1235 E:1239 ||| JJ
fractures  ||| S:1239 E:1249 ||| NN
for  ||| S:1249 E:1253 ||| IN
the  ||| S:1253 E:1257 ||| DT
CKD  ||| S:1257 E:1261 ||| NNP
group  ||| S:1261 E:1267 ||| NN
( ||| S:1267 E:1268 ||| -LRB-
HR ||| S:1268 E:1270 ||| NNP
,  ||| S:1270 E:1272 ||| ,
1.16  ||| S:1272 E:1277 ||| CD
[ ||| S:1277 E:1278 ||| -LRB-
1.06-1.27 ||| S:1278 E:1287 ||| NNP
] ||| S:1287 E:1288 ||| -RRB-
) ||| S:1288 E:1289 ||| -RRB-
,  ||| S:1289 E:1291 ||| ,
but  ||| S:1291 E:1295 ||| CC
this  ||| S:1295 E:1300 ||| DT
association  ||| S:1300 E:1312 ||| NN
was  ||| S:1312 E:1316 ||| VBD
attenuated  ||| S:1316 E:1327 ||| VBN
in  ||| S:1327 E:1330 ||| IN
competing  ||| S:1330 E:1340 ||| VBG
risk  ||| S:1340 E:1345 ||| NN
models  ||| S:1345 E:1352 ||| NNS
accounting  ||| S:1352 E:1363 ||| NN
for  ||| S:1363 E:1367 ||| IN
mortality  ||| S:1367 E:1377 ||| NN
( ||| S:1377 E:1378 ||| -LRB-
SHR ||| S:1378 E:1381 ||| NNP
,  ||| S:1381 E:1383 ||| ,
1.14  ||| S:1383 E:1388 ||| CD
[ ||| S:1388 E:1389 ||| -LRB-
1.03-1.27 ||| S:1389 E:1398 ||| NNP
] ||| S:1398 E:1399 ||| -RRB-
) ||| S:1399 E:1400 ||| -RRB-
.  ||| S:1400 E:1402 ||| .
Both  ||| S:1402 E:1407 ||| DT
death  ||| S:1407 E:1413 ||| NN
and  ||| S:1413 E:1417 ||| CC
hip  ||| S:1417 E:1421 ||| JJ
fracture  ||| S:1421 E:1430 ||| NN
rates  ||| S:1430 E:1436 ||| NNS
are  ||| S:1436 E:1440 ||| VBP
increased  ||| S:1440 E:1450 ||| VBN
( ||| S:1450 E:1451 ||| -LRB-
by  ||| S:1451 E:1454 ||| IN
83 ||| S:1454 E:1456 ||| CD
%  ||| S:1456 E:1458 ||| NN
and  ||| S:1458 E:1462 ||| CC
16 ||| S:1462 E:1464 ||| CD
% ||| S:1464 E:1465 ||| NN
,  ||| S:1465 E:1467 ||| ,
respectively ||| S:1467 E:1479 ||| RB
)  ||| S:1479 E:1481 ||| -RRB-
in  ||| S:1481 E:1484 ||| IN
CKD  ||| S:1484 E:1488 ||| NNP
patients ||| S:1488 E:1496 ||| NNS
.  ||| S:1496 E:1498 ||| .
However ||| S:1498 E:1505 ||| RB
,  ||| S:1505 E:1507 ||| ,
the  ||| S:1507 E:1511 ||| DT
association  ||| S:1511 E:1523 ||| NN
between  ||| S:1523 E:1531 ||| IN
CKD  ||| S:1531 E:1535 ||| NNP
and  ||| S:1535 E:1539 ||| CC
hip  ||| S:1539 E:1543 ||| JJ
fractures  ||| S:1543 E:1553 ||| NN
is  ||| S:1553 E:1556 ||| VBZ
attenuated  ||| S:1556 E:1567 ||| VBN
when  ||| S:1567 E:1572 ||| WRB
an  ||| S:1572 E:1575 ||| DT
excess  ||| S:1575 E:1582 ||| NN
of  ||| S:1582 E:1585 ||| IN
mortality  ||| S:1585 E:1595 ||| NN
is  ||| S:1595 E:1598 ||| VBZ
taken  ||| S:1598 E:1604 ||| VBN
into  ||| S:1604 E:1609 ||| IN
account ||| S:1609 E:1616 ||| NN
.  ||| S:1616 E:1618 ||| .
A  ||| S:1618 E:1620 ||| DT
competing  ||| S:1620 E:1630 ||| JJ
risk  ||| S:1630 E:1635 ||| NN
with  ||| S:1635 E:1640 ||| IN
death  ||| S:1640 E:1646 ||| NN
must  ||| S:1646 E:1651 ||| MD
be  ||| S:1651 E:1654 ||| VB
considered  ||| S:1654 E:1665 ||| VBN
in  ||| S:1665 E:1668 ||| IN
future  ||| S:1668 E:1675 ||| JJ
analyses  ||| S:1675 E:1684 ||| NNS
of  ||| S:1684 E:1687 ||| IN
association  ||| S:1687 E:1699 ||| NN
between  ||| S:1699 E:1707 ||| IN
CKD  ||| S:1707 E:1711 ||| NNP
and  ||| S:1711 E:1715 ||| CC
any  ||| S:1715 E:1719 ||| DT
health  ||| S:1719 E:1726 ||| NN
outcomes ||| S:1726 E:1734 ||| NNS
.  ||| S:1734 E:1736 ||| .
